Ovid Therapeutics vs Xenon Pharmaceuticals
OVID and XENE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How OVID and XENE compare
Xenon Pharmaceuticals is the larger company, worth 7.9 times as much as Ovid Therapeutics ($3.9B against $496M).
Ovid Therapeutics grew revenue faster over the last twelve months (−78.0% versus −100% for Xenon Pharmaceuticals).
Ovid Therapeutics scores higher on the StockData Score (9 against 7 for Xenon Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | OVID | XENE |
|---|---|---|
| Size and price | ||
| Market cap | $496M | $3.9B |
| Share price | $2.54 | $40.48 |
| Change, 1 year | 92.4% | 2.0% |
| Change, 5 years | −26.2% | 39.6% |
| Beta (5Y) | 1.22 | 0.62 |
| Employees | 23 | 370 |
| StockData Score | ||
| Total score | 9 (better) | 7 |
| Valuation score | 0 | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 2 (better) | 1 |
| Health score | 6 | 6 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 342× | – |
| P/B | 2.5× (better) | 3.4× |
| FCF yield | – | −9.1% |
| Growth | ||
| Revenue growth (TTM) | −78.0% (better) | −100% |
| Revenue growth, 5Y average | −10.5% (better) | −25.3% |
| Profitability | ||
| Operating margin | −4700% | – |
| Net margin | −2971% | – |
| Return on equity | −35.4% (better) | −50.3% |
| Return on invested capital | −191% (better) | −251% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 11.97 | 21.19 (better) |
| Altman Z-score | 9.96 | 41.77 (better) |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 75.3% | 104% |
| Held by insiders | 13.6% | 0.17% |
| Insider net buying, 12 months | −$29.3K (better) | −$20.3M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 10.8% | 7.6% |
Go deeper
- OVID stock overview
- OVID income statement
- OVID valuation and score
- XENE stock overview
- XENE income statement
- XENE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.